Cipla will invest €15 million in Ethris in order to develop mRNA-based medicines
The investment will enable Cipla and Ethris to form a long-term strategic partnership for the development of messenger RNA (mRNA)-based therapies, as well as accelerate Cipla's participation in the mRNA space, allowing it to provide access to cutting-edge solutions developed by Ethris for developing countries, according to a press release.
admin
Cipla's wholly owned UK subsidiary has invested EUR 15 million in Ethris, a global leader in delivering mRNAs directly to the respiratory system, including inhalation delivery.
The investment will enable Cipla and Ethris to form a long-term strategic partnership for the development of messenger RNA (mRNA)-based therapies, as well as accelerate Cipla's participation in the mRNA space, allowing it to provide access to cutting-edge solutions developed by Ethris for developing countries, according to a press release.
The agreement gives Ethris a foothold in Cipla's main emerging markets. "This relationship accelerates our innovation journey and helps us to provide access to cutting-edge healthcare solutions to our patients. We anticipate that mRNA-based medicines will be one of Cipla's primary innovation levers. This inhaled mRNA technology represents a paradigm shift in the delivery mechanism, and this collaboration maintains Cipla's position in respiratory medicine, in line with our goal of achieving worldwide lung leadership," stated Umang Vohra, MD & Global CEO of Cipla.
"This inhaled mRNA technology represents a paradigm shift in the delivery mechanism, and this agreement supports Cipla's position in respiratory medicine, which aligns with our goal of achieving worldwide lung leadership," Vohra noted.
